Patients With Brain Metastases From HER2-positive Breast Cancer

Summary

The purpose of this study is to determine the optimal sequences of combined trastuzumab emtansine (T-DM1) and whole-brain radiotherapy in patients presenting brain metastases from HER2-positive breast cancer in terms of acute toxicities and blood/cerebrospinal fluid T-DM1 pharmacokinetics.

Timeline

Start

2014-02

Primary completion

2017-02

Completion

2017-03

Drugs

Indications